BRAF and melanoma: After the results of several respective RCTs, the Food and Drug Administration (FDA) approved combination vemurafenib-plus-cobimetinib, dabrafenib-plus-trametinib, and encorafenib-plus-binimetinib for patients with melanoma, and this adjuvant treatment became a new standard of care for patients with BRAF-mutant melanoma.